Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

489 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines.
Hernandez N, Bucciol G, Moens L, Le Pen J, Shahrooei M, Goudouris E, Shirkani A, Changi-Ashtiani M, Rokni-Zadeh H, Sayar EH, Reisli I, Lefevre-Utile A, Zijlmans D, Jurado A, Pholien R, Drutman S, Belkaya S, Cobat A, Boudewijns R, Jochmans D, Neyts J, Seeleuthner Y, Lorenzo-Diaz L, Enemchukwu C, Tietjen I, Hoffmann HH, Momenilandi M, Pöyhönen L, Siqueira MM, de Lima SMB, de Souza Matos DC, Homma A, Maia MLS, da Costa Barros TA, de Oliveira PMN, Mesquita EC, Gijsbers R, Zhang SY, Seligman SJ, Abel L, Hertzog P, Marr N, Martins RM, Meyts I, Zhang Q, MacDonald MR, Rice CM, Casanova JL, Jouanguy E, Bossuyt X. Hernandez N, et al. Among authors: homma a. J Exp Med. 2019 Sep 2;216(9):2057-2070. doi: 10.1084/jem.20182295. Epub 2019 Jul 3. J Exp Med. 2019. PMID: 31270247 Free PMC article.
Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.
Bastard P, Michailidis E, Hoffmann HH, Chbihi M, Le Voyer T, Rosain J, Philippot Q, Seeleuthner Y, Gervais A, Materna M, de Oliveira PMN, Maia MLS, Dinis Ano Bom AP, Azamor T, Araújo da Conceição D, Goudouris E, Homma A, Slesak G, Schäfer J, Pulendran B, Miller JD, Huits R, Yang R, Rosen LB, Bizien L, Lorenzo L, Chrabieh M, Erazo LV, Rozenberg F, Jeljeli MM, Béziat V, Holland SM, Cobat A, Notarangelo LD, Su HC, Ahmed R, Puel A, Zhang SY, Abel L, Seligman SJ, Zhang Q, MacDonald MR, Jouanguy E, Rice CM, Casanova JL. Bastard P, et al. Among authors: homma a. J Exp Med. 2021 Apr 5;218(4):e20202486. doi: 10.1084/jem.20202486. J Exp Med. 2021. PMID: 33544838 Free PMC article.
Serious adverse events associated with yellow fever vaccine.
de Menezes Martins R, Fernandes Leal Mda L, Homma A. de Menezes Martins R, et al. Among authors: homma a. Hum Vaccin Immunother. 2015;11(9):2183-7. doi: 10.1080/21645515.2015.1022700. Hum Vaccin Immunother. 2015. PMID: 26090855 Free PMC article.
Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study.
de Menezes Martins R, Maia MLS, de Lima SMB, de Noronha TG, Xavier JR, Camacho LAB, de Albuquerque EM, Farias RHG, da Matta de Castro T, Homma A; Collaborative Group for Studies on Duration of Immunity from Yellow Fever Vaccine. de Menezes Martins R, et al. Among authors: homma a. Vaccine. 2018 Jun 27;36(28):4112-4117. doi: 10.1016/j.vaccine.2018.05.041. Epub 2018 May 18. Vaccine. 2018. PMID: 29784469 Free PMC article.
Phase I safety and immunogenicity study of a Brazilian serogroup B vaccine.
Martins RM, Périssé ARS, Camacho LAB, Leal ML, Maia MLS, Homma A, Jessouroun E. Martins RM, et al. Among authors: homma a. Braz J Infect Dis. 2021 Nov-Dec;25(6):101652. doi: 10.1016/j.bjid.2021.101652. Epub 2021 Nov 16. Braz J Infect Dis. 2021. PMID: 34793713 Free PMC article. Clinical Trial.
Covid-19 pandemic, R&D, vaccines, and the urgent need of UBUNTU practice.
Homma A, Carvalho ACC, Fialho BC, Gadelha CAG, Toscano CM, Krieger MA, Siqueira MM, Goldbaum M, Lima NVT, Savino W. Homma A, et al. Lancet Reg Health Am. 2021 Sep;1:100020. doi: 10.1016/j.lana.2021.100020. Epub 2021 Jul 24. Lancet Reg Health Am. 2021. PMID: 34386790 Free PMC article. No abstract available.
Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
Campi-Azevedo AC, Reis LR, Peruhype-Magalhães V, Coelho-Dos-Reis JG, Antonelli LR, Fonseca CT, Costa-Pereira C, Souza-Fagundes EM, da Costa-Rocha IA, Mambrini JVM, Lemos JAC, Ribeiro JGL, Caldas IR, Camacho LAB, Maia MLS, de Noronha TG, de Lima SMB, Simões M, Freire MDS, Martins RM, Homma A, Tauil PL, Vasconcelos PFC, Romano APM, Domingues CM, Teixeira-Carvalho A, Martins-Filho OA. Campi-Azevedo AC, et al. Among authors: homma a. Front Immunol. 2019 Sep 26;10:2192. doi: 10.3389/fimmu.2019.02192. eCollection 2019. Front Immunol. 2019. PMID: 31616412 Free PMC article. Clinical Trial.
17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study.
Martins RM, Maia Mde L, Farias RH, Camacho LA, Freire MS, Galler R, Yamamura AM, Almeida LF, Lima SM, Nogueira RM, Sá GR, Hokama DA, de Carvalho R, Freire RA, Pereira Filho E, Leal Mda L, Homma A. Martins RM, et al. Among authors: homma a. Hum Vaccin Immunother. 2013 Apr;9(4):879-88. doi: 10.4161/hv.22982. Epub 2013 Jan 30. Hum Vaccin Immunother. 2013. PMID: 23364472 Free PMC article. Clinical Trial.
489 results